Trial Profile
Phase II Study Of Iressa [gefitinib] (ZD 1839) In Locally Advanced And/Or Metastatic Synovial Sarcoma Expressing HER1/EGFR1.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Synovial sarcoma
- Focus Therapeutic Use
- 01 Oct 2005 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Sep 2005 New trial record.